Metraipolis › archive › dc_21672d43e3e7

Efficacy of SGLT2 inhibitors in preventing end-stage kidney disease in patients with IgA nephropathy: a scoping review — Europe PMC PMID:42145733

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42145733
DOI
10.3389/fmed.2026.1812783
License (as archived)
solo-consultazione
Archived
2026-11-02T23:53:35.842Z
SHA-256 of the archived text
6400173667fb36f1a619cb50392ca9f779814294134184e9a834977e00c8a478
Stable URL of this page
https://metraipolis.com/documento/dc_21672d43e3e7

How to cite

Efficacy of SGLT2 inhibitors in preventing end-stage kidney disease in patients with IgA nephropathy: a scoping review — Europe PMC PMID:42145733 — Europe PMC (en), https://europepmc.org/article/MED/42145733 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_21672d43e3e7 (Metraipolis archive dc_21672d43e3e7, sha256 6400173667fb36f1a619cb50392ca9f779814294134184e9a834977e00c8a478)
BibTeX
@misc{dc21672d43e3e7,
  title = {Efficacy of SGLT2 inhibitors in preventing end-stage kidney disease in patients with IgA nephropathy: a scoping review — Europe PMC PMID:42145733},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42145733},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_21672d43e3e7; sha256 6400173667fb36f1a619cb50392ca9f779814294134184e9a834977e00c8a478},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42145733. Agents can read the archived copy with the MCP tool read_document.